Search Result

Results for "

osteoclast differentiation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (2) Apoptosis (12) Autophagy (9) Bacterial (7) c-Fms (4) c-Kit (3) CaMK (1) Cathepsin (2) Dipeptidyl Peptidase (1) Dopamine β-hydroxylase (1) Drug Derivative (1) Endogenous Metabolite (3) ERK (2) Glyoxalase (GLO) (1) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (4) Isotope-Labeled Compounds (1) JNK (2) MMP (2) Monoamine Oxidase (1) NF-κB (10) NO Synthase (3) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (1) p38 MAPK (5) Parasite (1) PDGFR (1) Phosphatase (1) PI3K (2) PKA (2) PPAR (2) RANKL/RANK (3) Reactive Oxygen Species (3) STING (1) Toll-like Receptor (TLR) (1) TRP Channel (1) VD/VDR (1) VEGFR (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (3) Endocrinology (2) Infection (1) Inflammation/Immunology (22) Metabolic Disease (21) Neurological Disease (4)

By Targets:

Akt (1)

AMPK (2)

Apoptosis (12)

Autophagy (9)

Bacterial (7)

c-Fms (4)

c-Kit (3)

CaMK (1)

Cathepsin (2)

Dipeptidyl Peptidase (1)

Dopamine β-hydroxylase (1)

Drug Derivative (1)

Endogenous Metabolite (3)

ERK (2)

Glyoxalase (GLO) (1)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (4)

Isotope-Labeled Compounds (1)

JNK (2)

MMP (2)

Monoamine Oxidase (1)

NF-κB (10)

NO Synthase (3)

NOD-like Receptor (NLR) (1)

Nucleoside Antimetabolite/Analog (1)

p38 MAPK (5)

Parasite (1)

PDGFR (1)

Phosphatase (1)

PI3K (2)

PKA (2)

PPAR (2)

RANKL/RANK (3)

Reactive Oxygen Species (3)

STING (1)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

VD/VDR (1)

VEGFR (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (3)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (22)

Metabolic Disease (21)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: CD3 CD6 CD2 Neprilysin CD47 FLT3 Anaplastic lymphoma kinase (ALK) P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1098

Velutin	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
Velutin is an aglycone extracted from Flammulina velutipes, with inhibitory activity against melanin biosynthesis. Velutin reduces osteoclast differentiation and down-regulates HIF-1α through the NF-κB pathway .

HY-N9359

Toddaculin	Apoptosis	Cardiovascular Disease
Toddaculin is a natural coumarin that can induce differentiation and apoptosis in leukemic cells. Toddaculin suppresses excess osteoclast activity and enhances osteoblast differentiation and mineralization. Toddaculin also exhibits anti-inflammatory activity .

HY-N6624

Skullcapflavone II	Bacterial	Inflammation/Immunology
Skullcapflavone II, a flavonoid derived from Scutellaria baicalensis, has anti-inflammatory, anti-microbial activities. Skullcapflavone II regulates osteoclast differentiation, survival, and function. Skullcapflavone II exerts potent antimicrobial activity against M. aurum and M. bovis BCG .

HY-N0805A

Alisol B	Others	Metabolic Disease
Alisol B is a potentially novel therapeutic compound for bone disorders by targeting the differentiation of osteoclasts as well as their functions.

HY-169703

SPA0355	RANKL/RANK p38 MAPK Akt NF-κB	Inflammation/Immunology
SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .

HY-W641445

ELP-004	TRP Channel	Inflammation/Immunology
ELP-004 is a TRPC channel inhibitor and inhibtis TRPC channel-mediated Ca ²⁺ entry. ELP-004 is an osteoclast inhibitor and inhibits osteoclast differentiation. ELP-004 inhibits basal Ca ²⁺ and related NFATc1 translocation in inflammatory osteoclastogenesis. ELP-004 reduces bone erosion in a mouse model of rheumatoid arthritis .

HY-168090

Anti-osteoporosis agent-11	p38 MAPK NF-κB RANKL/RANK	Endocrinology
Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC₅₀ value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .

HY-115720

Betulinic acid derivative-1	Drug Derivative	Inflammation/Immunology
Betulinic acid derivative-1 exhibits distinguished activities on inhibiting osteoclast (OC) differentiation with an IC₅₀ value of 1.86 μM.

HY-N11494

Dauricumine	NF-κB	Others
Dauricumine is a chlorinated alkaloid that inhibits NF-κB ligand-induced differentiation of mouse bone marrow-derived macrophages into multinucleated osteoclasts .

HY-N11514

Anti-osteoporosis agent-2	Others	Inflammation/Immunology
Anti-osteoporosis agent-2 (Compound 10) is an anti-osteoporosis agent. Anti-osteoporosis agent-2 inhibits differentiation on osteoclast induced by RANKL .

HY-13777

Zoledronic Acid Maximum Cited Publications 14 Publications Verification Zoledronate; CGP 42446; CGP42446A; ZOL 446	Apoptosis Autophagy Bacterial	Metabolic Disease Cancer
Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .

HY-13777A

Zoledronic acid monohydrate Maximum Cited Publications 14 Publications Verification Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate	Apoptosis Autophagy Bacterial	Metabolic Disease Cancer
Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects .

HY-N12836

Peniditerpenoid A	Others	Metabolic Disease
Peniditerpenoid A is a di-seco-indole diterpenoid. Peniditerpenoid A decreases the expression of p-IkBαby RANKL induced. Peniditerpenoid A inhibits RANKL induced osteoclast differentiation. Peniditerpenoid A has the potential for the research of osteoporosis .

HY-W008634

Bropirimine 1 Publications Verification	Toll-like Receptor (TLR)	Cancer
Bropirimine is a synthetic agonist for toll-like receptor 7 (TLR7). Bropirimine inhibits differentiation of osteoclast precursor cells into osteoclasts via TLR7-mediated production of IFN-β. Bropirimine is an orally active immunomodulator that has demonstrated anticancer activity in transitional cell carcinoma in situ (CIS) in both the bladder and upper urinary tract .

HY-N3646

Cudratricusxanthone A	Others	Others Neurological Disease Inflammation/Immunology Cancer
Cudratricusxanthone A is isolated from Cudrania tricuspidata, and has anti-inflammatory, hepatoprotective, and anti-proliferative activities. Cudratricusxanthone A inhibits osteoclast differentiation and function in RAW 264.7 cells and mouse bone marrow monocytes .

HY-124478

Ethyl gentisate Ethyl 2,5-dihydroxybenzoate	Phosphatase	Metabolic Disease
Ethyl gentisate (Ethyl 2,5-dihydroxybenzoate) is a dual modulator for cell differentiation, that enhances the osteogenic differentiation of human mesenchymal stem cells (hMSCs) and alkaline phosphatase activity, inhibits RANKL-activated osteoclastogenesis in RAW264.7 cells, and balances the bone remodeling process .

HY-13777B

Zoledronic acid disodium tetrahydrate Zoledronate disodium tetrahydrate; CGP 42446 disodium tetrahydrate; CGP42446A disodium tetrahydrate; ZOL 446 disodium tetrahydrate	Apoptosis Autophagy Bacterial	Metabolic Disease Cancer
Zoledronic Acid (Zoledronate) disodium tetrahydrate is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid disodium tetrahydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid disodium tetrahydrate also has anti-cancer effects .

HY-N1098R

Velutin (Standard)	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
Colchiceine (Standard) is the analytical standard of Colchiceine. This product is intended for research and analytical applications. Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis .

HY-155550

CSF1R-IN-17	c-Fms	Inflammation/Immunology
CSF1R-IN-17 (compound 9) is a potent and selective CSF1R antagonist, with an IC₅₀ of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation .

HY-13777R

Zoledronic Acid (Standard)	Apoptosis Autophagy Bacterial	Metabolic Disease Cancer
Zoledronic Acid (Standard) is the analytical standard of Zoledronic Acid. This product is intended for research and analytical applications. Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .

HY-13777AR

Zoledronic acid (monohydrate) (Standard)	Apoptosis Autophagy Bacterial	Metabolic Disease Cancer
Zoledronic acid (monohydrate) (Standard) is the analytical standard of Zoledronic acid (monohydrate). This product is intended for research and analytical applications. Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects .

HY-145491

Resolvin D5	ERK NF-κB	Inflammation/Immunology
Resolvin D5 is a prolytic mediator (SPM) with anti-inflammatory activity derived from oxidized lipids DHA. Resolvin D5 inhibits Th17 cell differentiation and promotes regulatory T cell differentiation, and inhibits CD4+ T cell proliferation. Resolvin D5 attenuates osteoclast differentiation and interferes with osteoclastogenesis. Resolvin D5 also regulates ERK phosphorylation and nuclear translocation of NF-kappaB. Resolvin D5 could be used in rheumatoid arthritis research .

HY-N12507

Eupenicisirenin C	STING NF-κB	Others
Eupenicisirenin C (compound 1) is a sirenin derivative. Eupenicisirenin C has strong NF-κB inhibitory activities. Eupenicisirenin C suppresses effects on cGAS-STING pathway. Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophage cells .

HY-13777S

Zoledronic acid-d5 Zoledronate-d₅; CGP 42446-d₅; CGP42446A-d₅; ZOL 446-d₅	Bacterial Apoptosis Autophagy Isotope-Labeled Compounds	Metabolic Disease Cancer
Zoledronic acid-d₅ is deuterated labeled Zoledronic Acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .

HY-149472

Anti-osteoporosis agent-4	NF-κB PI3K	Inflammation/Immunology
Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC₅₀ value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation .

HY-N13219

Angelica Extract	Others	Metabolic Disease
Angelica Extract is an angelica extract, and its components include: Ligustilide. Angelica Extract can effectively inhibit the differentiation of osteoclasts, regulate osteoclastogenesis and/or bone loss. Angelica Extract has the potential to be used in the study of various bone diseases caused by excessive bone resorption. .

HY-W012980

Isovaleric acid	Endogenous Metabolite AMPK PKA	Metabolic Disease
Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .

HY-123503

Salicortin	JNK NF-κB	Neurological Disease Inflammation/Immunology
Salicortin, a phenolic glycoside, has been isolated from many plants such as Populus and Salix species. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways. Salicortin has anti-amnesic, anti-adipogenic, and immune-modulatory activity .

HY-158311

Anti-osteoporosis agent-8	RANKL/RANK p38 MAPK NF-κB	Endocrinology
Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC₅₀ is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model .

HY-124824

Methyl gerfelin	Glyoxalase (GLO)	Others
Methyl gerfelin inhibits osteoclast differentiation by binding 3 major cellular proteins: glyoxalase 1 (GLO1), sterol binding protein 2 (SCP2), and small glutamine-rich tetratricopeptide repeat containing protein A (SGTA). Methyl gerfelin is a potent GLO1 inhibitor related to the flavonoid class .

HY-118482

Sauristolactam Saurolactam	Others	Neurological Disease
Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells . Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation .

HY-W012980R

Isovaleric acid (Standard)	Endogenous Metabolite AMPK PKA	Metabolic Disease
Isovaleric acid (Standard) is the analytical standard of Isovaleric acid. This product is intended for research and analytical applications. Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .

HY-155960

SH491	Others	Inflammation/Immunology
SH491 (Compound 33) is an antiosteoporosis agent. SH491 inhibits RANKL-induced osteoclast differentiation on bone-marrow-derived monocytes (BMMs) (IC₅₀: 11.8 nM). SH491 inhibits the expression of osteoclastogenesis-related marker genes (TRAP, CTSK, MMP-9, and ATPase v0d2) and proteins (TRAP, CTSK, MMP-9) .

HY-B0119

Risedronic acid sodium 1 Publications Verification Risedronate sodium	Parasite Apoptosis	Infection Metabolic Disease Cancer
Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC₅₀ of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .

HY-124958

NDMC101	NF-κB Dipeptidyl Peptidase	Metabolic Disease Inflammation/Immunology
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al .

HY-13838

PLX647	c-Fms c-Kit	Cancer
PLX647 is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC₅₀s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC₅₀s=91 and 130 nM, respectively) .

HY-13838A

PLX647 dihydrochloride	c-Fms c-Kit	Inflammation/Immunology Cancer
PLX647 dihydrochloride is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC₅₀s of 28 and 16 nM, reapectively. PLX647 dihydrochloride shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC₅₀s=91 and 130 nM, respectively) .

HY-P4373

Hepcidin-1 (mouse)	Cathepsin MMP	Metabolic Disease
Hepcidin-1 (mouse) is an endogenous peptide hormone involved in the regulation of iron homeostasis. Hepcidin-1 (mouse) upregulates mRNA levels of TRAP, cathepsin K, and MMP-9 and increases TRAP-5b protein secretion. Hepcidin-1 (mouse) downregulates the level of FPN1 protein and increases intracellular iron. Hepcidin-1 (mouse) facilitates osteoclast differentiation .

HY-134314

8-Nitro-cGMP	Autophagy Endogenous Metabolite Nucleoside Antimetabolite/Analog	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
8-Nitro-cGMP is an electrophilic second messenger of redox signaling that can form a protein-S-cGMP adduct in s-guanylation process. 8-Nitro-cGMP is an autophagy inducer. 8-Nitro-cGMP promotes RANKL-induced osteoclast differentiation from macrophages. 8-Nitro-cGMP has vasodilator effect, and ameliorates the vascular endothelial dysfunction in diabetic mice .

HY-10408

Ki20227 5 Publications Verification	c-Fms VEGFR c-Kit PDGFR	Inflammation/Immunology
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .

HY-N0721

Neoandrographolide Neoandrographiside	ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 CaMK NO Synthase Reactive Oxygen Species Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .

HY-P4373A

Hepcidin-1 (mouse) (TFA)	Cathepsin MMP	Inflammation/Immunology
Hepcidin-1 (mouse) TFA is an endogenous peptide hormone involved in the regulation of iron homeostasis. Hepcidin-1 (mouse) TFA upregulates mRNA levels of TRAP, cathepsin K, and MMP-9 and increases TRAP-5b protein secretion. Hepcidin-1 (mouse) TFA downregulates the level of FPN1 protein and increases intracellular iron. Hepcidin-1 (mouse) TFA facilitates osteoclast differentiation .

HY-168336

E0924G	PPAR	Metabolic Disease
E0924G is an orally active activator for PPARδ with EC₅₀ of 2.82 μM. E0924G promotes the upregulation of osteoprotegerin (OPG) with an EC₅₀ of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibites F-actin ring formation in RAW264.7 macrophages. E0924G regulates the bone density and bone loss in ovariectomized (OVX) and age-related osteoporosis models .

HY-W016409

Ethyl 3,4-dihydroxybenzoate 1 Publications Verification Protocatechuic acid ethyl ester	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species NO Synthase Autophagy Apoptosis	Metabolic Disease Cancer
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-127090

Muramyl dipeptide 4 Publications Verification MDP	p38 MAPK NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide is an inducer of bone formation through induction of Runx2. Muramyl dipeptide directly enhances osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide is a NLRP1 agonist .

HY-12398

TEI-9647 1 Publications Verification	VD/VDR	Metabolic Disease Inflammation/Immunology
TEI-9647, a Vitamin D₃ Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)₂D₃. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)₂D₃. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .

HY-N7204

4-Hydroxyderricin 1 Publications Verification	Monoamine Oxidase Dopamine β-hydroxylase Apoptosis	Neurological Disease Inflammation/Immunology
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is an orally active, potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC₅₀ of 3.43 μM. 4-Hydroxyderricin also mildly inhibits dopamine β (DBH)-hydroxylase activity. 4-Hydroxyderricin has antidepressant activity, anti-allergic, anti-diabetic, anti-oxidant, and antitumor effects. 4-Hydroxyderricin promotes apoptosis and cell cycle arrest through regulating PI3K/AKT/mTOR pathway in hepatocellular cells. 4-Hydroxyderricin inhibits osteoclast formation and accelerates osteoblast differentiation . 4-Hydroxyderricin is promising for research of inflammatory diseases .

HY-W016409R

Ethyl 3,4-dihydroxybenzoate (Standard) Protocatechuic acid ethyl ester (Standard)	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species NO Synthase Autophagy Apoptosis	Metabolic Disease Cancer
Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Cat. No.	Product Name	Target	Research Area